Relation Between On-Treatment Increments in Serum High-Density Lipoprotein Cholesterol Levels and Cardiac Mortality in Patients With Coronary Heart Disease (from the Bezafibrate Infarction Prevention Trial)
- 1 February 2006
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 97 (4) , 466-471
- https://doi.org/10.1016/j.amjcard.2005.09.078
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary EventsJAMA, 2001
- Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery DiseaseCirculation, 2000
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999
- Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)The American Journal of Cardiology, 1993
- Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart StudyJAMA, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemiaAtherosclerosis, 1985